NEW YORK (GenomeWeb News) – Horizon Discovery announced on its website today that it has inked a collaborative agreement with Janssen Pharmaceutica division Ortho Biotech Oncology Research & Development.

Cambridge, UK-based Horizon said that the deal covers the licensing of certain of its X-MAN cell lines including major cancer-causing genes and their matched normal genetic backgrounds. Horizon said that the cell lines could help the J&J unit to gather information related to selectivity and mode of action of drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.